Researchers discover genes that suppress lymphoma in mice

RNA is making a comeback. For years researchers all-but-ignored RNA, assuming much of it was junk or served such simple purpose that it wasn't worth researching. That's all changing.

Researchers from New York's Cold Spring Harbor Laboratory suppressed the activity of hundreds of candidate tumor suppressing genes in mice using a technology called RNA interference. What they found was at least 10 genes that, once switched off, caused a rapid acceleration of the development of lymphomas in the mice. Furthermore, there seemed to be some specificity related t o these genes in their context, meaning that tumor suppressing genes for lymphoma don't suppress tumors in other cancers.

What it all may lead to is better immunotherapy drugs but also the possibility that some such drugs might help suppress one gene's ability to promote, say, a lung tumor, but wind up encouraging that same gene to promote the development of, say, lymphoma.

Typical. But did you expect anything less from cancer? Me neither.

The researchers published their findings in the journal Cancer Cell.

Blog Category: 

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap